A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations - TVP-1012/133
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms PRESTO
- Sponsors Teva Pharmaceutical Industries
- 27 Dec 2007 Status changed from in progress to completed according to ClinicalTrials.gov.
- 07 Nov 2005 New trial record.